TB-500 · BPC-157 · GHK-Cu — Systemic Repair, Healing and Collagen Synthesis
A three-compound synergistic protocol combining systemic tissue repair and angiogenesis (TB-500), localised healing and nerve regeneration (BPC-157), and collagen synthesis with anti-inflammatory action (GHK-Cu). Optimised for bone, skin, connective tissue and systemic recovery.
The GLOW Stack is a three-compound protocol combining TB-500, BPC-157 and GHK-Cu for comprehensive tissue repair with a particular emphasis on systemic healing, bone repair, collagen synthesis and skin regeneration. It differs from the KLOW Stack in that it omits KPV (the anti-inflammatory immune modulator) and includes TB-500 as the primary systemic driver — making it better suited for bone, skin and connective tissue applications versus KLOW's more localised soft tissue and gut focus.
Thymosin Beta-4 analogue is the systemic powerhouse of the GLOW stack. Unlike BPC-157 which tends to act locally, TB-500 distributes throughout the body — promoting cell migration, new blood vessel formation (angiogenesis) and stem cell differentiation at injury sites across multiple tissue types simultaneously. This systemic distribution makes it particularly valuable for spinal and bone conditions where precise local injection is difficult.
TB-500's angiogenesis mechanism is critical for bone healing — new blood vessel formation into bone repair sites is one of the rate-limiting steps in fracture and density recovery. Research in cardiac and skeletal muscle has shown TB-500 restores function in aged and damaged tissue through mechanisms that complement BPC-157's fibroblast-driven repair.
Body Protection Compound-157 provides the local tissue repair component. Its fibroblast migration, growth factor upregulation and anti-inflammatory signalling properties are well documented across 36+ published studies. In the context of spinal and bone applications, BPC-157's neurological healing properties are particularly relevant — it has demonstrated nerve regeneration and neuroprotective effects in animal models, making it applicable for spinal conditions where nerve involvement is present.
BPC-157 also upregulates VEGFR2 and promotes angiogenesis locally — complementing TB-500's systemic vascular effects with targeted local vascular support at specific injury sites.
GHK-Cu (copper tripeptide) is a naturally occurring peptide found in human plasma that plays a fundamental role in tissue remodelling. In the context of bone health and skin, its properties are particularly significant. GHK-Cu directly stimulates osteoblast differentiation and bone matrix synthesis — the cellular process of building new bone — while simultaneously promoting collagen, elastin and glycosaminoglycan production that forms the structural scaffolding bone mineralises onto.
For osteoporosis and bone density applications, GHK-Cu's osteoblast activation is mechanistically aligned with the underlying deficit — insufficient bone building activity relative to bone breakdown. Applied topically over the affected spinal area, GHK-Cu penetrates effectively through skin and reaches underlying tissue, providing a non-injection option for direct local application.
GHK-Cu also has documented neurotrophic properties — promoting nerve growth factor expression and supporting nerve tissue health — further relevant for spinal applications.
Both stacks share BPC-157 and GHK-Cu as core components. The key differences are:
For osteoporosis specifically, the GLOW stack addresses the condition through multiple pathways: BPC-157 accelerates bone healing and promotes local angiogenesis at damaged sites; TB-500 provides systemic vascular support and stem cell recruitment to bone tissue; GHK-Cu directly stimulates osteoblast activity and collagen matrix production. This combination addresses both the structural deficit (insufficient bone matrix) and the vascular supply needed to support bone repair.
The stack is best paired with the nutritional foundations that osteoporosis requires — Vitamin D3 (10,000 IU), K2 MK-7 (200mcg), magnesium glycinate (400mg) and resistance training, which provides the mechanical loading stimulus that signals bone to increase density regardless of supplementation.
All three components have demonstrated clean safety profiles in published research. TB-500 and BPC-157 have been used in veterinary medicine and preclinical research without significant adverse effects. GHK-Cu is a naturally occurring human peptide with extensive use in both research and cosmetic applications. No significant drug interactions have been documented. As with all angiogenesis-promoting compounds, individuals with active cancer or precancerous conditions should exercise caution and consult a physician before use.